The team found that LDL in these patients exhibits a misfolded structure that promotes aggregation and oxidation, key mechanisms in atherosclerosis development. This discovery opens new avenues for therapeutic strategies aimed at preventing LDL structural dysfunction and reducing cardiovascular complications.
The SOFT ICMAB/U6-Nanbiosis service played a crucial role in the biophysical characterization of the samples, providing advanced techniques to analyze biomolecular interactions with surfaces. As part of the Singular Scientific and Technical Infrastructure (ICTS) NANBIOSIS, this unit offers specialized support in nanobiotechnology and bioengineering.
This research highlights the importance of cutting-edge scientific infrastructures like the SOFT ICMAB/U6-Nanbiosis service in advancing our understanding of the molecular basis of cardiovascular diseases and fostering medical innovation.
